|
|
Post by bill on Oct 12, 2018 15:12:54 GMT -5
Does anyone have a bunch of November 16 $2 Calls? Need expert explains and advise to sell or buy more. - Easy answer... Unless you know something the rest of us don't, doing anything with any November 16 calls is simply an outright gamble; something significant may move the price or not. If you sell that call and the price jumps several dollars, it will be really expensive. If you buy the call and nothing happens you lose your investment. Just head to the casino. You'll have a better time  . |
|
|
|
Post by mike0475 on Oct 12, 2018 15:15:37 GMT -5
What about nov 23 2 call?
|
|
|
|
Post by peppy on Oct 12, 2018 15:20:28 GMT -5
|
|
|
|
Post by cedafuntennis on Oct 12, 2018 15:27:07 GMT -5
On the other hand, how about selling some puts instead? If the price goes up, you will likely keep the premium. If it remains the same, you either keep the premium or buy it a little cheaper. I don't expect the price to drop below the 1.5 mark, but who knows with MNKD.
|
|
|
|
Post by sportsrancho on Oct 12, 2018 15:38:05 GMT -5
Does anyone have a bunch of November 16 $2 Calls? Need expert explains and advise to sell or buy more. Everybody I know that has those thinks there’s a big announcement coming between now and then:-) I think I spent a couple hundred dollars on a crapshoot so I have very few of them. If I had a lot of them I’d roll them over and up a couple months. |
|
|
|
Post by brotherm1 on Oct 12, 2018 15:58:19 GMT -5
15,586 share lot just went through at 16:40 at 1.60
|
|
|
|
Post by mnholdem on Oct 12, 2018 18:58:53 GMT -5
I still prefer long-term option plays. Today I took a chance and made a low-ball bid on 2021 $2 calls and it filled shortly before EOD trading. A lot can (and I think will) happen in 26 months. Much riskier to bet on the stock price spiking within 5 weeks.
Like I said, it’s my preference. There are a couple of events coming up that may pay off for those Nov calls though. The Agreement between MannKind and Biomm S.A. states that the financial terms will be determined once Afrezza gets approval from the Brazilian regulatory authority (ANSIVA) so the market has yet to hear the deal, which could be imminent and include upfront $ and expected royalties on sales which CEO Castagna stated could begin as soon as 1Q19.
Following FTC no-action against the UTC deal we should quickly see information on the timeline of the Phase 3 clinical trial of TreT, which will be developed and funded by UTC. That will provide Wall Street with an estimated date of completion and NDA filing, notwithstanding the announcement of a 2nd API to be developed by UTC.
There’s India, whose approval process could be completed within six months of registration for an FDA-approved drug with an API as commonly accepted globally as is insulin (human).
There are two other API in the pipeline and a potential of partnerships for either or both.
Finally, Castagna stated earlier this year that MannKind planned to have registered Afrezza in countries that account for more than 50% of diabetes patients throughout the world. For that to happen, I think China must come into play, either via MannKind itself or a global partner.
A lot can happen in a brief amount of time, so those Nov calls may yield a handsome return. Of course, if these announcements come in December, you’re screwed.
Good fortune to you.
|
|
|
|
Post by brotherm1 on Oct 12, 2018 21:23:21 GMT -5
About 10k shares traded just before after hours close $1.65.
|
|
|
|
Post by tomtabb on Oct 14, 2018 9:57:53 GMT -5
I still prefer long-term option plays. Today I took a chance and made a low-ball bid on 2021 $2 calls and it filled shortly before EOD trading. A lot can (and I think will) happen in 26 months. Much riskier to bet on the stock price spiking within 5 weeks. Like I said, it’s my preference. There are a couple of events coming up that may pay off for those Nov calls though. The Agreement between MannKind and Biomm S.A. states that the financial terms will be determined once Afrezza gets approval from the Brazilian regulatory authority (ANSIVA) so the market has yet to hear the deal, which could be imminent and include upfront $ and expected royalties on sales which CEO Castagna stated could begin as soon as 1Q19. Following FTC no-action against the UTC deal we should quickly see information on the timeline of the Phase 3 clinical trial of TreT, which will be developed and funded by UTC. That will provide Wall Street with an estimated date of completion and NDA filing, notwithstanding the announcement of a 2nd API to be developed by UTC. There’s India, whose approval process could be completed within six months of registration for an FDA-approved drug with an API as commonly accepted globally as is insulin (human). There are two other API in the pipeline and a potential of partnerships for either or both. Finally, Castagna stated earlier this year that MannKind planned to have registered Afrezza in countries that account for more than 50% of diabetes patients throughout the world. For that to happen, I think China must come into play, either via MannKind itself or a global partner. A lot can happen in a brief amount of time, so those Nov calls may yield a handsome return. Of course, if these announcements come in December, you’re screwed. Good fortune to you. Anything new about the India approval process? It's been five months and neither Mannkind nor afrezza still show up anywhere on Cipla/s website: www.cipla.com/en/search.html?searchword=afrezza&searchphrase=all |
|
|
|
Post by peppy on Oct 15, 2018 15:26:23 GMT -5
MNKD Nasdaq real time volume, 1,023,006 shares MNKD Nasdaq summary volume, 1,789,935 shares. www.nasdaq.com/symbol/mnkd$1.65. + .05. + 3% |
|
|
|
Post by mytakeonit on Oct 16, 2018 0:54:58 GMT -5
If scripts go as planned ... well my plans anyway ... we'll be at $2 at the end of Halloweenie.
More great news is that I just learned that my taking baby aspirins for almost 50 years means that my ovaries will be cancer free.
|
|
|
|
Post by peppy on Oct 16, 2018 6:16:51 GMT -5
|
|
|
|
Post by peppy on Oct 16, 2018 8:07:47 GMT -5
A break and hold above $1.72,
$1.78, $1.85, $1.93, $1.98. (from the wedge starting sept 25, these are the targets off the 15min.)
I would think price should be able to hit $1.98 today,
we will see
|
|
|
|
Post by peppy on Oct 16, 2018 11:14:14 GMT -5
A break and hold above $1.72, $1.78, $1.85, $1.93, $1.98. (from the wedge starting sept 25, these are the targets off the 15min.) I would think price should be able to hit $1.98 today, we will see slowly, price heading up. 1,425,519 shares traded real time, in 2 3/4 hours. MNKD $1.81. +0.16. +9.69% www.nasdaq.com/symbol/mnkd/real-timeShort Interest 9/28/18 : 40,836,920 Days to cover : 13.788654 Short Interest 9/14/18 : 36,069,282 Change : 4,767,638 ~ 1/3 of shares are short. it would be nice if the squeeze starts now. |
|
|
|
Post by bobbyboy on Oct 16, 2018 11:33:17 GMT -5
Every time the pps reaches the HOD the shorts pile on. One would think the shorts are a bit paranoid.
|
|
.
